CF Therapy Kalydeco Receives Approval in the European Union

The European Commission has approved the use of the CF therapy Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.

| 1 min read

Kalydeco is the first drug to treat the underlying cause of CF -- a defective gene and its protein product, known as CFTR. Earlier this year, the U.S. Food and Drug Administration approved Kalydeco for people with the G551D mutation of CF in the United States.

In people with the G551D mutation, Kalydeco helps improve lung function and lower sweat chloride levels and helps patients gain weight - all key indicators that the drug is working.

The European Commission's decision comes only two months after the European Medicines Agency, which oversees drug approvals in the European Union, recommended the approval of Kalydeco.

Kalydeco was developed by Vertex with significant scientific, clinical and funding support from the Cystic Fibrosis Foundation.

Additional Resources

Share this article
About the CF Foundation | CFTR Modulators
Recent news
CF Foundation Establishes Health Equity Awards to Advance Research Toward Optimal Health Outcomes
News | 5 min read
CF Foundation Honors the Legacy of Joe O’Donnell
News | 4 min read
CF Foundation Invests up to $5M in Clarametyx Biosciences to Develop a New Anti-Bacterial Therapy 
News | 2 min read
You might also be interested in...
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.